PLX5622 Reduces Disease Severity in Lethal CNS Infection by Off-Target Inhibition of Peripheral Inflammatory Monocyte Production
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
PLX5622 is a CSF-1R inhibitor and microglia-depleting reagent, widely used to investigate the biology of this central nervous system (CNS)-resident myeloid population, but the indirect or off-target effects of this agent remain largely unexplored. In a murine model of severe neuroinflammation induced by West Nile virus encephalitis (WNE), we showed PLX5622 efficiently depleted both microglia and a sub-population of border-associated macrophages in the CNS. However, PLX5622 also significantly depleted mature Ly6C hi monocytes in the bone marrow (BM), inhibiting their proliferation and lethal recruitment into the infected brain, reducing neuroinflammation and clinical disease scores. Notably, in addition, BM dendritic cell subsets, plasmacytoid DC and classical DC, were depleted differentially in infected and uninfected mice. Confirming its protective effect in WNE, cessation of PLX5622 treatment exacerbated disease scores and was associated with robust repopulation of microglia, rebound BM monopoiesis and markedly increased inflammatory monocyte infiltration into the CNS. Monoclonal anti-CSF-1R antibody blockade late in WNE also impeded BM monocyte proliferation and recruitment to the brain, suggesting that the protective effect of PLX5622 is via the inhibition of CSF-1R, rather than other kinase targets. Importantly, BrdU incorporation in PLX5622-treated mice, suggest remaining microglia proliferate independently of CSF-1 in WNE. Our study uncovers significantly broader effects of PLX5622 on the myeloid lineage beyond microglia depletion, advising caution in the interpretation of PLX5622 data as microglia-specific. However, this work also strikingly demonstrates the unexpected therapeutic potential of this molecule in CNS viral infection, as well as other monocyte-mediated diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis
Yona, S., Kim, K.-W., Wolf, Y., Mildner, A., Varol, D., Breker, M., Strauss-Ayali, D., Viukov, S., Guilliams, M., Misharin, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.12.001 · Cited by 3,245 · cited 5×
“The loss of this sink either by depletion of these cells or by CSF-1R blockade could thus result in increased CSF-1 levels (7, 59).”
BackgroundInfluentialIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 2×
“However, our growing understanding of the inextricable importance of the brain microenvironment in instructing myeloid phenotype and function, has driven an increasing emphasis on work in vivo (29, 30).”
BackgroundAn environment-dependent transcriptional network specifies human microglia identity
Gosselin, D., Skola, D., Coufal, N. G., Holtman, I. R., Schlachetzki, J. C. M., Sajti, E., Jaeger, B. N., O’Connor, C., Fitzpatrick, C., Pasillas, M. P., et al. (2017) · Science · doi:10.1126/science.aal3222 · Cited by 1,220 · cited 1×
“However, our growing understanding of the inextricable importance of the brain microenvironment in instructing myeloid phenotype and function, has driven an increasing emphasis on work in vivo (29, 30).”
BackgroundDevelopmental and Functional Heterogeneity of Monocytes
Guilliams, M., Mildner, A., & Yona, S. (2018) · Immunity · doi:10.1016/j.immuni.2018.10.005 · Cited by 973
Spangenberg, E., Severson, P. L., Hohsfield, L. A., Crapser, J., Zhang, J., Burton, E. A., Zhang, Y., Spevak, W., Lin, J., Phan, N. Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11674-z · Cited by 939 · cited 3×
“Previous studies failed to demonstrate any impact on peripheral myeloid cells even after 7 months of treatment with PLX5622 (33), although these studies were focused on circulating blood leukocytes and the phenotypic markers used to examine the BM compartment were insufficient to identify the various BM populations de…”
BackgroundResultCSF-1 regulation of the wandering macrophage: complexity in action
Pixley, F. J., & Stanley, E. R. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.016 · Cited by 807
Huang, Y., Xu, Z., Xiong, S., Sun, F., Qin, G., Hu, G., Wang, J., Zhao, L., Liang, Y.-X., Wu, T., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0090-8 · Cited by 595 · cited 2×
“In the second group (PLX-Ctrl), after 21 days we replaced PLX5622-formulated chow with control chow (AIN-76A) from dpi 0 (the day of infection) onwards, to enable the replenishment of microglial numbers via proliferation of surviving microglia (34).”
BackgroundMethodDagher, N. N., Najafi, A. R., Kayala, K. M. N., Elmore, M. R. P., White, T. E., Medeiros, R., West, B. L., & Green, K. N. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0366-9 · Cited by 505 · cited 2×
“4 PLX5622 Inhibits Monocyte Production in the Bone Marrow, Thereby Reducing Their Lethal Infiltration Into the CNS To determine whether the protective effect of PLX5622 was due to depletion of microglia or an off-target effect, we reduced PLX5622 to a dose which was insufficient to reduce microglia numbers (50, 51) by…”
BackgroundTherapeutic Inflammatory Monocyte Modulation Using Immune-Modifying Microparticles
Getts, D. R., Terry, R. L., Getts, M. T., Deffrasnes, C., Müller, M., van Vreden, C., Ashhurst, T. M., Chami, B., McCarthy, D., Wu, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007563 · Cited by 378
Self-citationGetts, D. R., Terry, R. L., Getts, M. T., Müller, M., Rana, S., Shrestha, B., Radford, J., Van Rooijen, N., Campbell, I. L., & King, N. J. C. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080421 · Cited by 360
Self-citation
Cited by
Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits
Koutsodendris, N., Blumenfeld, J., Agrawal, A., Traglia, M., Grone, B., Zilberter, M., Yip, O., Rao, A., Nelson, M. R., Hao, Y., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00368-3 · Cited by 132
Low-dose PLX5622 treatment prevents neuroinflammatory and neurocognitive sequelae after sepsis
Mein, N., von Stackelberg, N., Wickel, J., Geis, C., & Chung, H.-Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02975-8 · Cited by 36
CNS macrophage contributions to myelin health
Hoffmann, A., & Miron, V. E. (2024) · Immunological Reviews · doi:10.1111/imr.13416 · Cited by 13
“74,75 Assessment of Csf1r −/− mice prior to their death at approximately 3 weeks of age, or administration of CSF1R inhibitors to developing mice, leads to a decrease in OPCs, mature oligodendrocytes and myelin.”
Metadata
- Authors
- Spiteri, A. G., Ni, D., Ling, Z. L., Macia, L., Campbell, I. L., Hofer, M. J., & King, N. J. C.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-03-25
- Volume
- 13
- Pages
- 851556-851556
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4220735854
- Cited by
- 83
- References
- 25
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PLX5622 Reduces Disease Severity in Lethal CNS Infection by Off-Target Inhibition of Peripheral Inflammatory Monocyte Production. https://app.cochat.ai/papers/10.3389/fimmu.2022.851556
- The paper
- Spiteri, A. G., Ni, D., Ling, Z. L., Macia, L., Campbell, I. L., Hofer, M. J., & King, N. J. C. (2022). PLX5622 Reduces Disease Severity in Lethal CNS Infection by Off-Target Inhibition of Peripheral Inflammatory Monocyte Production. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.851556
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.